Moreover, despite the relatively small increase in killing of target cells, trastuzumab could potentiate the NK cell anti-tumor response by strongly enhancing NK cell degranulation under normoxic and hypoxic conditions, especially against HER2 overexpressing target cells. Here, ERBB2 is linked to neoplasm.